What is Global Levothyroxine Sodium Market?
The Global Levothyroxine Sodium Market is a vast and dynamic sector that deals with the production, distribution, and sale of Levothyroxine Sodium, a medication used to treat thyroid hormone deficiency. This market is not confined to a specific region or country but spans across the globe, making it a significant player in the global pharmaceutical industry. The market's value was estimated at US$ 3604.2 million in 2022, and it is projected to reach US$ 4382.9 million by 2029. This growth is expected to occur at a Compound Annual Growth Rate (CAGR) of 2.8% from 2023 to 2029.
Oral, Injection in the Global Levothyroxine Sodium Market:
Levothyroxine Sodium is available in two forms: oral and injection. The oral form is the most common and is usually the first line of treatment for thyroid hormone deficiency. It is easy to administer and has a high absorption rate, making it the preferred choice for many patients and healthcare providers. On the other hand, the injection form is used in more severe cases or when the patient cannot take oral medication. Despite being less common, it plays a crucial role in the market due to its effectiveness in treating severe thyroid hormone deficiency.
Hospitals, Pharmacy, Others in the Global Levothyroxine Sodium Market:
The Global Levothyroxine Sodium Market serves various areas, including hospitals, pharmacies, and others. Hospitals are the largest consumers of Levothyroxine Sodium due to the high number of patients they treat. They use both the oral and injection forms of the medication, depending on the patient's condition. Pharmacies, on the other hand, mostly deal with the oral form of the medication, as it is the most commonly prescribed by doctors for home use. Other areas where Levothyroxine Sodium is used include clinics, nursing homes, and home healthcare.
Global Levothyroxine Sodium Market Outlook:
The market outlook for the Global Levothyroxine Sodium Market is promising. The market was valued at US$ 3604.2 million in 2022 and is expected to reach US$ 4382.9 million by 2029, growing at a CAGR of 2.8% during the forecast period 2023-2029. Abbvie was the largest company in the Levothyroxine Sodium industry, with a revenue market share of 23%, followed by Mylan Pharma, Merck, Pfizer, Lannett Company, Novartis, Fresenius Kabi, IBSA, Piramal Critical Care, and Abbott. North America is the largest Levothyroxine Sodium market, accounting for about 69% of the market share, followed by Europe with about 17% market share.
| Report Metric | Details |
| Report Name | Levothyroxine Sodium Market |
| Accounted market size in 2022 | US$ 3604.2 million |
| Forecasted market size in 2029 | US$ 4382.9 million |
| CAGR | 2.8% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Abbvie, Mylan Pharma, Merck, Pfizer, Lannett Company, Novartis, Fresenius Kabi, IBSA, Piramal Critical Care, Abbott |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
